Comparative Pharmacology
Head-to-head clinical analysis: BACI RX versus BACTROBAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACI RX versus BACTROBAN.
BACI-RX vs BACTROBAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.
Binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
None Documented
None Documented
Terminal half-life: 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in anuria. Clinical context: Dosing interval adjustment required for creatinine clearance <30 mL/min.
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Renal: 90-100% as unchanged drug via glomerular filtration; biliary/fecal: negligible.
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Category C
Category C
Topical Antibiotic
Topical Antibiotic